IOnctura’s CEO Catherine Pickering outlines the company’s business model and its approach to cancer R&D targeting the tumor microenvironment. She talks to Scrip’s John Hodgson about the company’s founding, technology and checkpoint inhibitor combination strategy. Pickering also discusses IOnctura’s financing goals for 2018.